MedPath

Intraoperative TAP Block After Repeat Cesarean

Not Applicable
Withdrawn
Conditions
Post-operative Pain
Interventions
Procedure: TAP Block Group
Registration Number
NCT05393908
Lead Sponsor
University of Massachusetts, Worcester
Brief Summary

The aim of this study is to perform a randomized trial to investigate if intraoperative surgeon administered TAP block reduces pain and use of oral and parenteral pain medications after repeat cesarean delivery. The investigators aim to compare surgeon administered TAP block with liposomal bupivacaine compared to standard treatment (i.e. no TAP block) with regard to the primary outcome of post-operative narcotic use.

Detailed Description

Transversus abdominis plane (TAP) block is a well-described technique to provide a field block for analgesia. It has been shown to be effective in postoperative analgesia after cesarean delivery. TAP blocks are commonly performed post-operatively by anesthesiologists using liposomal bupivacaine with ultrasound guidance. Liposomal bupivacaine is an FDA approved medication for post-surgical analgesia and available at UMass-Memorial Medical Center. Liposomal bupivacaine provides sustained release of medication for up to 120 hours. A recent multicenter randomized controlled trial demonstrated the efficacy of anesthesiologist administered TAP blocks using liposomal bupivacaine after cesarean delivery. Infiltration of the skin and fascia with liposomal bupivacaine after cesarean did not have an effect and this can be explained by the path that the pain fibers take through the TAP which makes them amenable to a TAP block while a superficial infiltration is ineffective.The aim of this study is to perform a randomized trial to investigate if intraoperative surgeon administered TAP block reduces pain and use of oral and parenteral pain medications after repeat cesarean delivery. The investigators aim to compare surgeon administered TAP block with liposomal bupivacaine compared to standard treatment (i.e. no TAP block) with regard to the primary outcome of post-operative narcotic use.

Recruitment & Eligibility

Status
WITHDRAWN
Sex
Female
Target Recruitment
40
Inclusion Criteria
  • Pregnant women presenting for elective repeat cesarean delivery at 37-42 weeks gestational age.
  • Pregnancy and delivery care obtained at UMass Memorial Medical Center
  • Patients able to provide written informed consent
  • English, Spanish, or Portuguese-speaking patients
Exclusion Criteria
  • Participants who are under the age of 18 years
  • Active labor.
  • Baseline pain score > 6.
  • Unable to provide informed consent.
  • Prisoners will be excluded from this research.
  • Narcotic use in the 2 weeks prior to delivery.
  • Active substance abuse.
  • Inability to take narcotic analgesia.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
TAP Block GroupTAP Block GroupParticipants will receive a surgeon administered TAP block consisting of liposomal bupivacaine during their repeat cesarean delivery.
Primary Outcome Measures
NameTimeMethod
Daily Narcotic Use in Morphine EquivalentsFrom time of surgery through postpartum day 4

Daily Narcotic Use in Morphine Equivalents

Secondary Outcome Measures
NameTimeMethod
Time to first administered narcotic (oral or parental)From time of surgery through postpartum day 4

Time to first administered narcotic (oral or parental) post cesarean delivery

Daily Maximum Pain ScoreFrom time of surgery through postpartum day 4

Daily Average Pain Score based on ten point pain scale (minimum 0, maximum 10) with higher numbers indicating worse pain

Daily Average Pain ScoreFrom time of surgery through postpartum day 4

Daily Average Pain Score based on ten point pain scale (minimum 0, maximum 10) with higher numbers indicating worse pain

Time to First AmbulationFrom time of surgery through postpartum day 4

Time to First Ambulation post cesarean delivery

Time to First Solid FoodFrom time of surgery through postpartum day 4

Time to First Solid Food

© Copyright 2025. All Rights Reserved by MedPath